RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer

RAS mutant (MT) metastatic colorectal cancer (mCRC) is resistant to MEK1/2 inhibition and remains a difficult-to-treat group. Therefore, there is an unmet need for novel treatment options for RASMT mCRC. RALA and RALB GTPases function downstream of RAS and have been found to be key regulators of sev...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Death Dis
Egile Nagusiak: Khawaja, Hajrah, Campbell, Andrew, Roberts, Jamie Z., Javadi, Arman, O’Reilly, Paul, McArt, Darragh, Allen, Wendy L., Majkut, Joanna, Rehm, Markus, Bardelli, Alberto, Di Nicolantonio, Federica, Scott, Christopher J., Kennedy, Richard, Vitale, Nicolas, Harrison, Timothy, Sansom, Owen J., Longley, Daniel B., Evergren, Emma, Van Schaeybroeck, Sandra
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596570/
https://ncbi.nlm.nih.gov/pubmed/33122623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-03131-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak